...
首页> 外文期刊>Scientific reports. >Exploring anticancer activity of structurally modified benzylphenoxyacetamide (BPA); I: Synthesis strategies and computational analyses of substituted BPA variants with high anti-glioblastoma potential
【24h】

Exploring anticancer activity of structurally modified benzylphenoxyacetamide (BPA); I: Synthesis strategies and computational analyses of substituted BPA variants with high anti-glioblastoma potential

机译:探索结构改性苯苄苯氧基乙酰胺(BPA)的抗癌活性; I:具有高抗胶质母细胞瘤电位的取代的BPA变体的合成策略和计算分析

获取原文
           

摘要

Structural variations of the benzylphenoxyacetamide (BPA) molecular skeleton were explored as a viable starting point for designing new anti-glioblastoma drug candidates. Hand-to-hand computational evaluation, chemical modifications, and cell viability testing were performed to explore the importance of some of the structural properties in order to generate, retain, and improve desired anti-glioblastoma characteristics. It was demonstrated that several structural features are required to retain the anti-glioblastoma activity, including a carbonyl group of the benzophenone moiety, as well as 4'-chloro and 2,2-dimethy substituents. In addition, the structure of the amide moiety can be modified in such a way that desirable anti-glioblastoma and physical properties can be improved. Via these structural modifications, more than 50 compounds were prepared and tested for anti-glioblastoma activity. Four compounds were identified (HR28, HR32, HR37, and HR46) that in addition to HR40 (PP1) from our previous study, have been determined to have desirable physical and biological properties. These include high glioblastoma cytotoxicity at low μM concentrations, improved water solubility, and the ability to penetrate the blood brain barrier (BBB), which indicate a potential for becoming a new class of anti-glioblastoma drugs.
机译:苄基苯氧基乙酰胺(BPA)分子骨架的结构变化被探索为设计新的抗胶质母细胞瘤候选物的可行起点。进行手工计算评估,化学修饰和细胞活力测试以探讨一些结构特性的重要性,以便产生,保留和改善所需的抗胶质母细胞瘤特征。结果证明,需要几种结构特征来保留抗胶质母细胞瘤活性,包括二苯甲酮部分的羰基,以及4'-氯和2,2-二甲基取代基。另外,可以以所需的抗胶质母细胞瘤和物理性质改善酰胺部分的结构。通过这些结构改性,制备了超过50种化合物并测试抗胶质母细胞瘤活性。鉴定了四种化合物(HR28,HR32,HR37和HR46),除了来自我们以前的研究的HR40(PP1)之外,已经确定具有理想的物理和生物学性质。这些包括在低μm浓度下的高胶质母细胞瘤细胞毒性,改善水溶性,以及穿透血脑屏障(BBB)的能力,这表明成为成为新一类抗胶质母细胞瘤药物的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号